Key result
Men in the highest quartile of plasma IGFBP-3 levels had a 71% reduced risk of prostate cancer compared with men in the lowest quartile (OR 0.29, 95% CI 0.11-0.64, Ptrend<0.001).
Why the study?
Are serum IGF-1 and IGFBP-3 levels associated with the risk of prostate cancer in a Korean population?
Case-Control (n=330)
No
Are serum IGF-1 and IGFBP-3 levels associated with the risk of prostate cancer in a Korean population?
In a Korean population, higher IGFBP-3 levels, but not IGF-1 levels, are inversely associated with prostate cancer risk.
Should not alter prostate cancer risk assessment; hypothesis-generating for IGFBP-3 in Koreans and needs prospective validation.
Purpose: Conflicting results have been reported for western populations on associations of serum insulin-like growth factor I (IGF-I) and major IGF-binding protein-3 (IGFBP-3) with the risk of prostate cancer. However, few data have been available for oriental populations. We undertook a matched case-control study in a low-risk Korean population to extend our knowledge about potential associations. Materials and Methods: Serum IGF-I and IGFBP-3 levels were determined for 330 men (165 cases and 165 healthy age-matched controls). Conditional logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between plasma IGF levels and prostate cancer. We also investigated the potential influence of the associations according to clinical risk for advanced disease at diagnosis. Results: We noted that the risks of prostate cancer were unrelated to the IGF-1 level and IGF-I/IGFBP-3 molar ratio. In contrast, a strong inverse association was observed between IGFBP-3 levels and the risk for prostate
No takes yet. Share an insight, caveat, or question.
Kim et al. (2009) conducted a case-control in Prostate cancer (n=330). Plasma IGFBP-3 levels vs. Lowest quartile of plasma IGFBP-3 levels was evaluated on Risk of prostate cancer (OR 0.29, 95% CI 0.11-0.64, p=<0.001). Men in the highest quartile of plasma IGFBP-3 levels had a 71% reduced risk of prostate cancer compared with men in the lowest quartile (OR 0.29, 95% CI 0.11-0.64, Ptrend<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: